167 related articles for article (PubMed ID: 2153347)
41. A comparison between Ki-67 antibody reactivity and other pathological variables in breast carcinoma.
Bilous AM; McKay M; Milliken J
Pathology; 1991 Oct; 23(4):282-5. PubMed ID: 1664511
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.
Lundy J; Thor A; Maenza R; Schlom J; Forouhar F; Testa M; Kufe D
Breast Cancer Res Treat; 1985; 5(3):269-76. PubMed ID: 2992647
[TBL] [Abstract][Full Text] [Related]
43. Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor.
Toi M; Wada T; Yamada H; Ohsaki A; Yamamoto A; Nakamura T; Niimoto M; Hattori T
Jpn J Surg; 1990 May; 20(3):327-30. PubMed ID: 2162976
[TBL] [Abstract][Full Text] [Related]
44. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables.
Stumpp J; Dietl J; Simon W; Geppert M
Gynecol Obstet Invest; 1992; 33(1):47-50. PubMed ID: 1373397
[TBL] [Abstract][Full Text] [Related]
45. Oestrogen receptors in human breast cancer: review of histopathological correlations and critique of histochemical methods.
Underwood JC
Diagn Histopathol; 1983; 6(1):1-22. PubMed ID: 6307615
[TBL] [Abstract][Full Text] [Related]
46. Potential value of hormone receptor assay in carcinoma in situ of breast.
Barnes R; Masood S
Am J Clin Pathol; 1990 Nov; 94(5):533-7. PubMed ID: 2173395
[TBL] [Abstract][Full Text] [Related]
47. Intermediate filament expression of ductal carcinoma cells in fine needle aspirates of the breast.
Heatley M; White J; Patterson A; Maxwell P; Whiteside C; Toner P
Acta Cytol; 1997; 41(3):717-20. PubMed ID: 9167690
[TBL] [Abstract][Full Text] [Related]
48. Estrogen receptors and histopathological evaluation of human breast cancer.
Sarría JA; Spitale L; Tobar C; Foresi AM
Eur J Gynaecol Oncol; 1987; 8(2):81-7. PubMed ID: 3032636
[TBL] [Abstract][Full Text] [Related]
49. A combined histological, immunocytochemical and biochemical approach in the evaluation of estrogen receptors in breast carcinomas.
Pietribiasi F; Gugliotta P; Racca S; Di Carlo F; Bussolati G
Int J Biol Markers; 1986; 1(1):9-14. PubMed ID: 2826620
[TBL] [Abstract][Full Text] [Related]
50. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.
Cattoretti G; Andreola S; Clemente C; D'Amato L; Rilke F
Br J Cancer; 1988 Apr; 57(4):353-7. PubMed ID: 3291921
[TBL] [Abstract][Full Text] [Related]
51. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.
Holck S; Pedersen L; Schiødt T; Zedeler K; Mouridsen H
Virchows Arch A Pathol Anat Histopathol; 1993; 422(6):475-9. PubMed ID: 8392769
[TBL] [Abstract][Full Text] [Related]
52. Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer.
Berger U; Wilson P; McClelland RA; Davidson J; Coombes RC
Hum Pathol; 1987 Dec; 18(12):1263-7. PubMed ID: 2824329
[TBL] [Abstract][Full Text] [Related]
53. Establishment and characterization of a cell line of human breast carcinoma origin.
Keydar I; Chen L; Karby S; Weiss FR; Delarea J; Radu M; Chaitcik S; Brenner HJ
Eur J Cancer (1965); 1979 May; 15(5):659-70. PubMed ID: 228940
[No Abstract] [Full Text] [Related]
54. Human breast cancer: heterogeneity of estrogen binding sites.
Poulsen HS; Jensen J; Hermansen C
Cancer; 1981 Oct; 48(8):1791-3. PubMed ID: 6269725
[TBL] [Abstract][Full Text] [Related]
55. The relationship between Barr bodies and cytoplasmic oestradiol receptors in human breast cancer.
Bishun NP; Smethurst M; Williams DC
Clin Oncol; 1979 Jun; 5(2):147-51. PubMed ID: 223790
[No Abstract] [Full Text] [Related]
56. Comparison between histologic type, estrogen receptor, and nuclear DNA content in mammary carcinoma.
Erhardt K; Auer G; Folin A; Silfverswärd C; Skoog L
Am J Clin Oncol; 1986 Feb; 9(1):83-9. PubMed ID: 3006475
[TBL] [Abstract][Full Text] [Related]
57. Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Galant C; Gala JL; Van Den Berge V; Berlière M; Haumont E; Horsmans Y
Pharmacol Toxicol; 2001 Mar; 88(3):142-6. PubMed ID: 11245409
[TBL] [Abstract][Full Text] [Related]
58. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors.
Vielh P; Chevillard S; Mosseri V; Donatini B; Magdelenat H
Am J Clin Pathol; 1990 Dec; 94(6):681-6. PubMed ID: 2244589
[TBL] [Abstract][Full Text] [Related]
59. Histology and cytometrics in human breast cancers assayed for the presence of prolactin receptors.
Codegone ML; Di Carlo R; Muccioli G; Bussolati G
Tumori; 1981 Dec; 67(6):549-52. PubMed ID: 6278686
[TBL] [Abstract][Full Text] [Related]
60. Ki-67 immunostaining in human breast tumors and its relationship to prognosis.
Wintzer HO; Zipfel I; Schulte-Mönting J; Hellerich U; von Kleist S
Cancer; 1991 Jan; 67(2):421-8. PubMed ID: 1845945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
